Melanoma
-
February 4: The Week in Cancer NewsCAR T-cell therapy effects continue 10 years after treatment and first T-cell receptor therapeutic approved for uveal melanoma.
by Eric Fitzsimmons
-
January 28: The Week in Cancer NewsPharmacies asked to stop turning immune-compromised people away for fourth shot, and fiber intake is associated with stronger immune response in people with melanoma.
by Marci A. Landsmann
-
January 14: The Week in Cancer NewsCancer mortality continues to go down, and a “real-world” study finds more than a third of active surveillance patients are lost to follow-up.
by Eric Fitzsimmons
-
December 10: The Week in Cancer NewsA new program specializes in concerns of gay and bisexual men with prostate cancer, and Black women found to have a higher risk of lymphedema after breast cancer.
by Eric Fitzsimmons
-
December 3: The Week in Cancer NewsSome cancer centers scrutinized for lack of pricing transparency, and an imaging drug helps surgeons better identify ovarian cancer with fluorescent lighting.
by Marci A. Landsmann
-
More Options for Treating MelanomaWith targeted drugs, immunotherapies and treatment combinations now available, people with advanced melanoma have choices to make.
by Kendall K. Morgan
-
July 9: The Week in Cancer NewsStudy shows cancer centers can improve coordination with physicians' practices in their networks, and cancer death rates in U.S. continue to decline.
by Marci A. Landsmann
-
Forward Look
What’s Next?Using fecal transplants to improve immunotherapy response
by Natalie Slivinski
-
Facts and Stats
Categorizing Skin CancerA knowledge of the different types of skin cancer can help you remain vigilant.
by Bradley Jones
-
How Long Do Immunotherapy Side Effects Last?For people with melanoma who receive immune checkpoint inhibitors after surgery, side effects can remain even after treatment has been completed. These chronic side effects are most often mild.
by Anna Goshua
